On 12 Nov 2026 Zoetis closed at $82.96, -32.6% this year; market cap $34.15bn, P/E 13.7.
Health Care · Pharmaceuticals · NYSE · United States
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
| Market cap | $34.15bn |
| P/E (trailing) | 13.7 |
| EPS (TTM) | $6.04 |
| Beta | 0.68 |
| Dividend | $2.12 |
| Dividend yield | 2.56% |
| Ex-dividend date | 30 Oct 2026 |
| Latest report | 5 Nov 2026 |
| Next earnings | 4 Feb 2027 |
| YTD | -32.6% |
| 1Y | -30.0% |
| 3Y | -19.9% |
| 5Y | -16.5% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $9.47bn | $2.67bn | $2.28bn |
| 2024 | $9.26bn | $2.49bn | $2.30bn |
| 2023 | $8.54bn | $2.34bn | $1.62bn |
| 2022 | $8.08bn | $2.11bn | $1.33bn |
| 2021 | $7.78bn | $2.04bn | $1.74bn |
Base value $91.68 (+10.5% vs price); 1 of 1 methods above the price. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.